Abstract PS4-07-01: Exploring the Impact of Circadian Timing and TIL Status on Immunotherapy Response in Breast Cancer

Clinical Cancer Research 2026

View at publisher
Authors: K. Nakamura, Kanako Saito, Rie Ito, M. Yoshida, Erina Hatakawa, Rena Yamakado, Miyuko Yoshikawa, S. Watanabe, N. Imai, M. Shibusawa, A. Noro, Y. Kozuka
+1 more K. Kawaguchi
DOI: 10.1158/1557-3265.sabcs25-ps4-07-01
Cited by: 0

Abstract

Abstract Background: Circadian rhythms regulate immune responses, but their clinical relevance in cancer immunotherapy remains underexplored. We investigated whether the timing of immune checkpoint inhibitor (ICI) administration, in conjunction with tumor-infiltrating lymphocyte (TIL) status, influences treatment efficacy in breast cancer. Methods: We conducted a retrospective analysis of two cohorts: a perioperative cohort receiving neoadjuvant ICI (n = 22, early-stage) and a metastatic cohort treated with ICI in the advanced setting (n = 18). For each patient, the median time of ICI administration was determined and dichotomized as morning (

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Circadian rhythm and melatonin Breast Cancer Treatment Studies

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
4_Supplement
Pages
PS4–07
Publication date
17 February 2026
Language
EN